Multiple sourcing Framework Contracts to speed up the development of and access to innovative medical countermeasures Next Generation Therapeutics for Infectious Diseases

pe of the call is expected to cover the development of innovative therapeutics to treat viral infections, ARDS or sepsis resulting from infections, including pathogen-targeted therapeutics (but not small molecules or monoclonal antibodies) and host-targeted therapeutics, among which but not only dir

ect-acting antivirals, indirect-acting antivirals and novel immune modulators. It may also cover innovative combinations therapies and products designed to be administered through alternative routes to IV. Broad spectrum therapeutics, patho